Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CR
CervoMed Inc. Common Stock
CRVO
Volume
87.87K
Next Earnings
November 6th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CR
CRVO
CR
CervoMed Inc. Common Stock
CRVO
News
·
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis
Mkt Cap
$34.0M
Volume
87.87K
Next Earnings
November 6th
Chart
Financials
Earnings
News
About
Insider
Filings
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis
CervoMed Inc. announced that its drug candidate neflamapimod has been selected for inclusion in the UK's EXPERTS-ALS platform, a government-funded clinical trial designed to rapidly test potential ALS treatments. The trial will initially evaluate neflamapimod in approximately 35 ALS patients over 18-24 weeks, with potential expansion to 80 patients. The selection is based on the drug's targeted mechanism of action and positive clinical data in dementia with Lewy bodies trials.
GlobeNewswire Inc. · Feb 18, 2026
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
CervoMed presented Phase 2b trial results showing neflamapimod significantly slows clinical progression in dementia with Lewy bodies, with most prominent improvements in patients without AD co-pathology. The company plans to initiate Phase 3 trials in 2026.
GlobeNewswire Inc. · Dec 4, 2025
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
CervoMed shared Phase 2b trial data showing neflamapimod treatment reduced neuroinflammation biomarkers in Dementia with Lewy Bodies patients, with promising results indicating potential disease progression slowing.
GlobeNewswire Inc. · Dec 2, 2025
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
CervoMed will present new data on neflamapimod, a potential treatment for Dementia with Lewy Bodies (DLB), at the 18th Clinical Trials on Alzheimer's Disease Conference, highlighting results from their Phase 2b RewinD-LB trial.
GlobeNewswire Inc. · Nov 24, 2025
Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream
EmergingGrowth.com announced the schedule for its 87th conference featuring presentations from multiple small-cap companies across various sectors on October 22-23, 2025, providing insights into emerging growth opportunities.
GlobeNewswire Inc. · Oct 22, 2025
CervoMed to Present at the Emerging Growth Conference
CervoMed, a clinical-stage company developing treatments for age-related neurologic disorders, will present at the Emerging Growth Conference on October 22, 2025, discussing their investigational drug neflamapimod for treating Dementia with Lewy Bodies.
GlobeNewswire Inc. · Oct 20, 2025
CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
CervoMed, a clinical-stage company developing treatments for neurologic disorders, will participate in the 4th Annual ROTH Healthcare Opportunities Conference in New York on October 9, 2025, presenting on small firms addressing major medical indications.
GlobeNewswire Inc. · Oct 2, 2025
CervoMed to Participate in Upcoming Investor Conferences
CervoMed, a clinical-stage company developing treatments for neurologic disorders, will participate in the H.C. Wainwright and Morgan Stanley Global Healthcare conferences in September 2025, presenting its investigational drug neflamapimod for Dementia with Lewy Bodies (DLB).
GlobeNewswire Inc. · Sep 3, 2025
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
CervoMed reported positive 32-week trial results for neflamapimod in treating Dementia with Lewy Bodies (DLB), showing a 54% risk reduction in clinical progression and significant reduction in neurodegeneration biomarkers.
GlobeNewswire Inc. · Jul 28, 2025
CervoMed to Present at the 8th International Lewy Body Dementia Conference
CervoMed, a clinical-stage company, announced that topline results from its Phase 2b RewinD-LB study of neflamapimod in dementia with Lewy bodies will be presented at the 8th International Lewy Body Dementia Conference in Amsterdam on January 31, 2025.
GlobeNewswire Inc. · Jan 29, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
CR
CRVO
CervoMed Inc. Common Stock
Buy
Sell
Market
Limit
Soon
CRVO
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any CRVO yet.
Related Tickers
Earnings